Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMJ4AWC)

• Drug Name: Cyclothiazide Drug Info
• Synonyms: Anhydron; Aquirel; Ciclotiazida; Ciclotiazide; Cyclothiazidum; Doburil; Fluidil; Renazide; Valmiran; Ciclotiazide [DCIT]; C 9847; MDi 193; Anhydron (TN); Ciclotiazida [INN-Spanish]; Cyclothiazidum [INN-Latin]; Lilly 35,483; Cyclothiazide [USAN:INN:BAN]; Cyclothiazide (JAN/USAN/INN); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-,1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-, 1,1-dioxide; 3-(bicyclo[2.2.1]hept-5-en-2-yl)-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2-4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(2-norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
• Therapeutic Class: Antihypertensive Agents
• Cross-matching ID:
  PubChem CID: 2910
  ChEBI ID: CHEMBL61593
  CAS Number: CAS 2259-96-3
  TTD Drug ID: D03CNS
  VARIDT Drug ID: DR00511

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Toxoplasmosis	-1.67	3.66e-2	103/112 (91.96%)	HSPA2;CD40LG;TNF;...
Spliceosome	-1.67	3.71e-2	101/150 (67.33%)	PCBP1;PUF60;SNRPF;...
Ribosome	-1.69	3.26e-2	113/158 (71.52%)	RPL38;RPS3A;RPL35A;...
Phagosome	-1.70	3.38e-2	118/152 (77.63%)	CALR;MARCO;CYBB;...
Th17 cell differentiation	-1.72	2.53e-2	95/107 (88.79%)	MAPK1;MAPK8;SMAD4;...
Viral myocarditis	-1.73	2.18e-2	53/60 (88.33%)	ACTB;HLA-E;EIF4G3;...
Protein processing in endoplasmic reticulum	-1.73	2.33e-2	127/171 (74.27%)	BCL2;MBTPS2;SEC13;...
Systemic lupus erythematosus	-1.76	2.01e-2	45/135 (33.33%)	CD40LG;TNF;C2;...
Notch signaling pathway	-1.82	1.20e-2	49/59 (83.05%)	APH1B;DLL3;TLE3;...
Proteasome	-1.85	8.31e-3	44/46 (95.65%)	PSMB7;PSMB2;PSMB1;...
Graft-versus-host disease	-1.86	7.83e-3	32/42 (76.19%)	TNF;HLA-E;HLA-DQB1;...
Leishmaniasis	-1.89	7.25e-3	67/77 (87.01%)	HLA-DQB1;IFNG;TGFB1;...
Type I diabetes mellitus	-1.89	8.16e-3	38/43 (88.37%)	GZMB;LTA;TNF;...
Asthma	-1.91	7.46e-3	25/31 (80.65%)	CD40LG;TNF;HLA-DQB1;...
Staphylococcus aureus infection	-1.93	6.53e-3	72/95 (75.79%)	HLA-DQB1;PTAFR;FGG;...
Autoimmune thyroid disease	-2.01	2.61e-3	46/53 (86.79%)	TSHB;GZMB;CD40LG;...
Inflammatory bowel disease	-2.06	0.00e+0	58/65 (89.23%)	MAF;IL23A;HLA-DQB1;...
Th1 and Th2 cell differentiation	-2.12	0.00e+0	80/92 (86.96%)	MAPK1;MAPK8;GATA3;...
Allograft rejection	-2.22	0.00e+0	32/38 (84.21%)	GZMB;CD40LG;TNF;...
Antigen processing and presentation	-2.42	0.00e+0	60/78 (76.92%)	CD8A;HSPA2;CALR;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H	Hide ▲